GlassScriptPhysician profile
Daniela Filip Kovacs
NPI 1659573624
$10,698.51
in general payments reported to CMS, 2019-2025
29 companies · $1,071 in 2025
The $1,071 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,266 · 2020: $885 · 2021: $1,247 · 2022: $1,187 · 2023: $695 · 2024: $3,347 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629 · Travel and Lodging: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.59 |
| Travel and Lodging | $1,485.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,138.92 | 2022-2024 | Indigo System |
| Medtronic Vascular, INC. | $1,133.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $964.74 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $955.45 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $953.10 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $906.49 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $891.90 | 2019-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $415.79 | 2019-2024 | Brilinta, Farxiga |
| Merck Sharp & Dohme LLC | $304.37 | 2021-2025 | Verquvo |
| Pfizer INC. | $271.37 | 2019-2025 | |
| Medtronic, INC. | $217.28 | 2021-2025 | Hawkone, Chocolate Pta Balloon Catheter, Micra |
| Cardiovascular Systems INC. | $210.81 | 2019-2021 | |
| Amgen INC. | $201.02 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $172.57 | 2019-2025 | Eliquis |
| Esperion Therapeutics, INC. | $171.62 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.17 | 2019-2025 | Jardiance |
| Teleflex LLC | $107.87 | 2023-2025 | Guideliner |
| Lantheus Medical Imaging, INC. | $104.61 | 2019-2022 | |
| Cook Medical LLC | $74.83 | 2019-2024 | Icast Covered Stent System, 6mmx22mmx120cm |
| Abbott Laboratories | $71.56 | 2021-2024 | Jeti Peripheral Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $53.09 | 2025 | |
| Boston Scientific Corporation | $47.07 | 2020-2023 | Ekosonic |
| Actelion Pharmaceuticals US, INC. | $38.58 | 2023 | Uptravi, Opsumit |
| Inari Medical, INC. | $38.39 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $22.02 | 2019 | |
| Acera Surgical, INC. | $21.15 | 2024 | Restrata Wound Matrix |
| Cardiva Medical, INC. | $18.12 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.03 | 2024 | |
| Acist Medical Systems, INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Filip Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.